BRCA2 and breast cancer: The expression of mesenchymal-like features resulting from complete or partial EMT can cause increased resistance to chemotherapeutic and targeted agents, therefore driving acquired resistance such as in the case of PARP inhibitor resistance in models of BRCA2-mutated mammary tumors [44–46].